GLP1R and metabolic dysfunction-associated steatohepatitis: Semaglutide, another GLP-1 receptor agonist, exhibited powerful improvements against NASH without worsening fibrosis at a dose of 0.4 mg compared to placebo in a phase II trial (Newsome et al., 2021).